| MeSH term | MeSH ID | Detail |
|---|---|---|
| Melanoma | D008545 | 69 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schwarz LJ et al. | An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. | 2017 | J. Natl. Cancer Inst. | pmid:29059433 |
| Chen SC et al. | Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). | 2017 | Cancer Chemother. Pharmacol. | pmid:29043411 |
| Li C et al. | Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. | 2017 | Cancer Chemother. Pharmacol. | pmid:29022084 |
| Cox K et al. | Emerging Therapeutic Strategies in Breast Cancer. | 2017 | South. Med. J. | pmid:28973703 |
| Diéras V et al. | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. | 2017 | Lancet Oncol. | pmid:28526536 |
| La Monica S et al. | Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. | 2017 | J. Exp. Clin. Cancer Res. | pmid:29202823 |
| Morimura O et al. | Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. | 2017 | Biochem. Biophys. Res. Commun. | pmid:28526406 |
| Fabi A et al. | Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? | 2017 | Future Oncol | pmid:29182361 |
| Menderes G et al. | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. | 2017 | Gynecol. Oncol. | pmid:28473206 |
| Zhang J et al. | Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis. | 2017 | Drug Des Devel Ther | pmid:29180848 |
| Moore KN et al. | Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. | 2017 | Cancer | pmid:28440955 |
| Ito K et al. | Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer. | 2017 | Bioconjug. Chem. | pmid:28402624 |
| Sun X et al. | Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. | 2017 | Bioconjug. Chem. | pmid:28388844 |
| Eckelmann D et al. | Spatial profiling of maytansine during the germination process of Maytenus senegalensis seeds. | 2017 | Fitoterapia | pmid:28385670 |
| Diaby V et al. | Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. | 2017 | Breast Cancer Res. Treat. | pmid:28840424 |
| Thuss-Patience PC et al. | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. | 2017 | Lancet Oncol. | pmid:28343975 |
| Sabbaghi M et al. | Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. | 2017 | Clin. Cancer Res. | pmid:28821558 |
| Beck A et al. | Strategies and challenges for the next generation of antibody-drug conjugates. | 2017 | Nat Rev Drug Discov | pmid:28303026 |
| Chuang JC et al. | ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. | 2017 | J Thorac Oncol | pmid:28167203 |
| Liu Y et al. | LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). | 2017 | J Pharm Biomed Anal | pmid:28131055 |
| Daniels B et al. | Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. | 2017 | BMJ Open | pmid:28119394 |
| Kosmin M et al. | Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. | 2017 | Target Oncol | pmid:28110417 |
| Andreev J et al. | Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. | 2017 | Mol. Cancer Ther. | pmid:28108597 |
| Schönfeld K et al. | Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. | 2017 | J Hematol Oncol | pmid:28077160 |
| Moore KN et al. | Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. | 2017 | J. Clin. Oncol. | pmid:28029313 |
| Geraud A et al. | Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. | 2017 | J. Neurooncol. | pmid:27995546 |
| Yap LW et al. | Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. | 2017 | Fetal Pediatr Pathol | pmid:27935326 |
| Zhao M et al. | Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema pretiosum. | 2017 | Appl. Biochem. Biotechnol. | pmid:27787765 |
| Chen SC et al. | Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. | 2017 | Br J Clin Pharmacol | pmid:28733983 |
| Iwamoto N et al. | LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. | 2017 | J Pharm Biomed Anal | pmid:28648785 |
| Seidel K et al. | Synthesis of Magnetic-Nanoparticle/Ansamitocin Conjugates-Inductive Heating Leads to Decreased Cell Proliferation In Vitro and Attenuation Of Tumour Growth In Vivo. | 2017 | Chemistry | pmid:28585348 |
| Lynce F et al. | SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. | 2017 | Oncologist | pmid:28314836 |
| Janjigian YY and Braghiroli MI | Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. | 2017 | Surg. Oncol. Clin. N. Am. | pmid:28279471 |
| Stefan N et al. | Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. | 2017 | Mol. Cancer Ther. | pmid:28258164 |
| Wang H et al. | Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity. | 2017 | Chem. Commun. (Camb.) | pmid:28195282 |
| Zhong P et al. | αβ Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. | 2017 | J Control Release | pmid:27986551 |
| Wang LL et al. | A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting. | 2017 | Chemistry | pmid:27935144 |
| Mercogliano MF et al. | TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. | 2017 | Clin. Cancer Res. | pmid:27698002 |
| Baldassarre T et al. | Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. | 2017 | Breast Cancer Res. | pmid:28974266 |
| Ning X et al. | Identification and Engineering of Post-PKS Modification Bottlenecks for Ansamitocin P-3 Titer Improvement in Actinosynnema pretiosum subsp. pretiosum ATCC 31280. | 2017 | Biotechnol J | pmid:28881098 |
| van Boxtel W et al. | Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. | 2017 | Oral Oncol. | pmid:28673692 |
| Ait-Oudhia S et al. | A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. | 2017 | AAPS J | pmid:28646408 |
| Lin J and Zhong JJ | Proteomic studies on anti-tumor agent ansamitocin P-3 producer Actinosynnema pretiosum in response to ammonium and isobutanol. | 2017 | Bioprocess Biosyst Eng | pmid:28382459 |
| Martin LP et al. | Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. | 2017 | Gynecol. Oncol. | pmid:28843653 |
| Wang H et al. | Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. | 2017 | Cancer Sci. | pmid:28388007 |
| Lambert JM and Morris CQ | Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. | 2017 | Adv Ther | pmid:28361465 |
| Socinski MA et al. | Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. | 2017 | Clin Lung Cancer | pmid:28341109 |
| Carvajal-Hausdorf DE et al. | Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. | 2017 | Gynecol. Oncol. | pmid:28196634 |
| Perez EA et al. | Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. | 2017 | J. Clin. Oncol. | pmid:28056202 |
| Parikh A et al. | Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. | 2017 | J Natl Compr Canc Netw | pmid:28040715 |